
Exact Sciences Corporation EBITDA | EXAS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Exact Sciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -81.4 M | -929 M | -101 M | -493 M | -761 M | -698 M | -218 M | -136 M | -103 M | -157 M | -155 M | -98.9 M | -45.3 M | -51.7 M | -28.4 M | -11.6 M | -9.17 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.17 M | -929 M | -240 M |
Quarterly EBITDA Exact Sciences Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.6 M | -15 M | -2.96 M | -83.4 M | -77.1 M | -9.1 M | 3.44 M | -76.1 M | - | 36.1 M | -49.4 M | -50.3 M | - | -113 M | -134 M | -154 M | - | -140 M | -150 M | -280 M | - | -150 M | -33.4 M | -66.4 M | -82.3 M | -13.8 M | -20.4 M | -61.7 M | -48.6 M | -26.6 M | -23.9 M | -32.2 M | -23 M | -27.8 M | -31.1 M | -35.4 M | -37.7 M | -38.1 M | -45 M | -45.4 M | -40.4 M | -43.3 M | -39.4 M | -34.4 M | -32.6 M | -29.9 M | -18.2 M | -15.5 M | -12.3 M | -10.3 M | -11.7 M | -10.6 M | -14 M | -12.3 M | -14.5 M | -10.5 M | -9.94 M | -7.58 M | -6.5 M | -4.34 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.1 M | -280 M | -45.3 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
-11.1 M | - | -8.98 % | $ 14.8 K | ||
|
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | ||
|
Renalytix AI plc
RNLX
|
-29.2 M | - | 5.66 % | $ 22.7 M | ||
|
Meridian Bioscience
VIVO
|
70.9 M | - | - | $ 1.49 B | ||
|
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | ||
|
Accelerate Diagnostics
AXDX
|
-33.9 M | - | -61.36 % | $ 2.46 M | ||
|
T2 Biosystems
TTOO
|
-48.8 M | - | -39.35 % | $ 313 K | ||
|
Syneos Health
SYNH
|
650 M | - | - | $ 4.46 B | ||
|
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
47.2 M | - | - | $ 21.2 M | ||
|
Quotient Limited
QTNT
|
-96.6 M | - | -11.32 % | $ 1.1 M | ||
|
Brainsway Ltd.
BWAY
|
1.39 M | $ 8.53 | -2.29 % | $ 290 M | ||
|
Burning Rock Biotech Limited
BNR
|
-33.1 M | $ 13.46 | 1.05 % | $ 142 M | ||
|
Medpace Holdings
MEDP
|
562 M | $ 609.81 | -3.81 % | $ 17.6 B | ||
|
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | ||
|
Surmodics
SRDX
|
3.05 M | - | - | $ 608 M | ||
|
RadNet
RDNT
|
214 M | $ 69.77 | 0.37 % | $ 5.25 B | ||
|
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M | ||
|
Psychemedics Corporation
PMD
|
-793 K | - | -1.84 % | $ 15.3 M | ||
|
IDEXX Laboratories
IDXX
|
1.51 B | $ 675.24 | -2.09 % | $ 54.3 B | ||
|
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
-22.2 M | $ 7.55 | -9.1 % | $ 57 M | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | ||
|
Agilent Technologies
A
|
1.77 B | $ 169.82 | -3.21 % | $ 48.2 B | ||
|
Charles River Laboratories International
CRL
|
428 M | $ 314.38 | -4.13 % | $ 15.6 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.13 B | $ 257.78 | -0.4 % | $ 28.6 B | ||
|
Danaher Corporation
DHR
|
5.44 B | $ 220.3 | -3.19 % | $ 157 B | ||
|
DexCom
DXCM
|
1.16 B | $ 79.02 | -1.46 % | $ 30.8 B | ||
|
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.44 | -6.15 % | $ 79.2 K | ||
|
Celcuity
CELC
|
-172 M | $ 53.32 | -5.31 % | $ 2.49 B | ||
|
Guardant Health
GH
|
-398 M | $ 145.9 | 0.21 % | $ 18.3 B | ||
|
BioNano Genomics
BNGO
|
-23.8 M | $ 0.82 | -7.56 % | $ 4.46 M | ||
|
Bioventus
BVS
|
101 M | $ 9.89 | -0.65 % | $ 659 M | ||
|
IQVIA Holdings
IQV
|
3.33 B | $ 245.67 | -1.92 % | $ 42.2 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.07 B | $ 367.68 | -0.44 % | $ 30.6 B | ||
|
Castle Biosciences
CSTL
|
-2.04 M | $ 32.69 | -2.14 % | $ 948 M | ||
|
Mettler-Toledo International
MTD
|
51.1 M | $ 1 667.59 | -2.3 % | $ 34.4 B | ||
|
Illumina
ILMN
|
1.08 B | $ 192.79 | -3.92 % | $ 29.9 B | ||
|
Natera
NTRA
|
-268 M | $ 273.11 | -5.8 % | $ 37.3 B | ||
|
Koninklijke Philips N.V.
PHG
|
2.55 B | $ 28.63 | -2.22 % | $ 27.1 B | ||
|
Fulgent Genetics
FLGT
|
-67 M | $ 24.03 | -3.03 % | $ 740 M | ||
|
CareDx, Inc
CDNA
|
-15.8 M | $ 69.9 | -2.81 % | $ 3.72 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M | ||
|
Biomerica
BMRA
|
-5.24 M | $ 1.09 | -0.46 % | $ 3.18 M | ||
|
Interpace Biosciences
IDXG
|
4.51 M | $ 4.4 | -4.35 % | $ 19.5 M | ||
|
Lantheus Holdings
LNTH
|
381 M | $ 102.12 | 0.01 % | $ 6.89 B | ||
|
Senseonics Holdings
SENS
|
-66.8 M | $ 8.03 | -9.88 % | $ 335 M | ||
|
Sotera Health Company
SHC
|
94.9 M | $ 15.92 | -1.82 % | $ 4.52 B | ||
|
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | ||
|
ICON Public Limited Company
ICLR
|
826 M | $ 186.79 | -1.88 % | $ 14.6 B |